More Big-name Pharma Firms Join NCATS Therapeutic Repurposing Effort | GenomeWeb

NEW YORK (GenomeWeb News) – The National Center for Advancing Translational Sciences said today that five additional pharmaceutical companies have joined its new program to enable researchers to study new uses for chemical compounds that have been set aside by drug makers

The five new participants in the NCATS program are Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical Research and Development, and Sanofi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.